文献速递乳腺癌支持与姑息治疗

早期乳腺癌年轻女性化疗所致卵巢功能衰竭的前瞻性分析

Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials.
PubMed 文献 · Eur J Cancer · 2021-06-08

该研究基于四项新辅助/辅助乳腺癌试验,对≤45岁、基线绝经前激素水平的早期乳腺癌患者分析化疗所致卵巢功能衰竭(CIOF)。CIOF与更好的无病生存相关,尤其在激素受体阳性或<30岁患者中。

要点

  • 化疗结束时85.1%的≤45岁早期乳腺癌患者发生CIOF。
  • CIOF后2年内89.2%的患者恢复绝经前激素水平。
  • CIOF与更好DFS相关,HR阳性者HR=2.69,<30岁者HR=4.87。

核心结论

  • 大多数绝经前早期乳腺癌患者化疗后发生CIOF,但2年内近所有患者恢复绝经前激素水平。
  • CIOF与更好的无病生存相关,尤其在激素受体阳性或年龄<30岁的患者中。

研究设计与样本

  • 前瞻性分析四项新辅助/辅助乳腺癌试验中≤45岁、基线绝经前激素水平的早期乳腺癌患者。
  • 共696例患者纳入分析,接受蒽环/紫杉类化疗。
  • 在基线、治疗结束及治疗后6、12、18、24个月采集血样,中心检测雌二醇和FSH定义CIOF,并评估AMH和窦卵泡计数。

主要发现

  • 治疗结束时85.1%(592/696)发生CIOF。
  • CIOF患者中,6个月时32.7%(48/147)恢复绝经前激素水平,12个月时57.9%(66/114),18个月时83.0%(73/88),24个月时89.2%(74/83)。
  • 24个月时,无CIOF患者中72.4%(21/29)AMH水平低,CIOF患者中100%(14/14)AMH水平低。
  • 4年DFS:无CIOF vs CIOF为65.9% vs 84.6%(HR=2.09,95%CI 1.37-3.19;P<0.001)。
  • 激素受体阳性亚组4年DFS:61.8% vs 87.5%(HR=2.69,95%CI 1.57-4.60;P<0.001);<30岁亚组:68.3% vs 92.6%(HR=4.87,95%CI 1.05-22.63;P=0.026)。

关键数值与推荐

  • CIOF定义:基线绝经前激素水平患者,中心检测雌二醇<52.2 ng/L且FSH>12.4 IU/L。
  • 卵巢储备评估指标包括AMH和窦卵泡计数。
  • 其他分析包括化疗所致闭经、绝经前激素水平恢复及无病生存。

临床怎么用

  • 对≤45岁早期乳腺癌化疗患者,应关注卵巢功能衰竭风险并向患者说明。
  • 化疗后2年内多数患者激素水平可恢复,但AMH低提示卵巢储备下降。
  • CIOF与更好DFS相关,尤其HR阳性或<30岁患者,但需结合其他因素综合评估。

局限性

  • CIOF后仅部分患者有后续激素测量,恢复率基于子集分析。
  • CIOF与DFS关联为探索性分析,不能推断因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Young women receiving chemotherapy for early breast cancer (EBC) have a high probability for ovarian failure, defined by chemotherapy-induced amenorrhea (CIA) as a surrogate. CIA is insufficiently reliable and reproducible. We analysed chemotherapy-induced ovarian failure (CIOF) by assessing hormone parameters, CIA, and antral follicle count (AFC). METHODS: Blood samples of women aged ≤45 years treated with anthracycline/taxane-based chemotherapy for EBC from four neoadjuvant/adjuvant trials were collected at baseline, at the end of treatment (EOT), and at 6, 12, 18, and 24 months after EOT. Centrally assessed oestradiol (cutoff <52.2 ng/L) and follicle-stimulating hormone (cutoff >12.4IU/L) were used to define CIOF for patients with baseline premenopausal hormone levels, anti-Müllerian hormone (AMH), and AFC to assess ovarian reserve. Further analyses included CIA, regain of premenopausal hormone levels, and disease-free survival (DFS) also in subgroups. RESULTS: Six hundred ninety-six patients aged ≤45 years had premenopausal hormone levels at baseline. Overall, 85.1% (592/696) experienced CIOF at EOT, and 147 of 592 had further hormone measurements after EOT. Of those, 32.7% (48/147) regained premenopausal hormone levels after 6 months, 57.9% (66/114) regained premenopausal hormone levels after 12 months, 83.0% (73/88) regained premenopausal hormone levels after 18 months, and 89.2% (74/83) regained premenopausal hormone levels after 24 months. After 24 months, 72.4% (21/29) of patients without CIOF and 100% (14/14) with CIOF had low AMH levels. Four-year DFS without CIOF versus CIOF was 65.9% versus 84.6% (hazard ratio [HR] = 2.09, 95% confidence interval [CI]: 1.37-3.19; P < 0.001); in hormone receptor positive 61.8% versus 87.5% (HR = 2.69, 95% CI: 1.57-4.60; P < 0.001); in <30 years 68.3% versus 92.6% (HR = 4.87, 95% CI: 1.05-22.63; P = 0.026). CONCLUSION: Most premenopausal women experienced CIOF after chemotherapy for EBC. After 2 years, nearly all regain premenopausal hormone levels. CIOF was associated with better DFS, especially in patients with hormone receptor-positive EBC or aged <30 years.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Furlanetto J, Marmé F, Seiler S, et al. Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials. Eur J Cancer. 2021. PMID: 34116270. doi:10.1016/j.ejca.2021.04.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。